Patent application number | Description | Published |
20090131682 | SUPPORTS FOR OLIGOMER SYNTHESIS - Universal linkers, their facile processes of manufacture and methods of using the same are provided. | 05-21-2009 |
20090306358 | SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS - The use of N-formamidino-5-amino-3H-1,2,4-dithiazole-3-thiones as novel, efficient sulfur-transfer reagents is disclosed. The sulfur transfer from these reagents to compounds containing P(III) atom, triphenylphosphine, 5′-O-DMT-thymidine 2-cyanoethyl-(N,N-diisopropyl)phosphoramidite, and 5′-O-DMT-3′-O-levulinyl dithymidilyl 2-cyanoethyl phosphite, was studied in solution by | 12-10-2009 |
20100234528 | SUPPORTS FOR OLIGOMER SYNTHESIS - Universal linkers, their facile processes of manufacture and methods of using the same are provided. | 09-16-2010 |
20110137021 | SULFUR TRANSFER REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS - The use of N-formamidino-5-amino-3H-1,2,4-dithiazole-3-thiones, 5-phenyl-3H-1,2,4-dithiazole-3-thiones, and derivatives thereof as novel, efficient sulfur-transfer reagents is disclosed. Sulfur transfer from these reagents to compounds containing a P(III) atom (e.g., triphenylphosphine, 5′-O-DMT-thymidine 2-cyanoethyl-(N,N-diisopropyl)phosphoramidite, and 5′-O-DMT-3′-O-levulinyl dithymidilyl 2-cyanoethyl phosphite), was studied in solution by | 06-09-2011 |
20120165547 | SUPPORTS FOR OLIGOMER SYNTHESIS - Universal linkers, their facile processes of manufacture and methods of using the same are provided. | 06-28-2012 |
Patent application number | Description | Published |
20120116360 | TREATMENT OF NEUROLOGICAL DISORDERS - This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution. | 05-10-2012 |
20140315851 | VITAMIN B6 DERIVATIVES OF NUCLEOTIDES, ACYCLONUCLEOTIDES AND ACYCLONUCLEOSIDE PHOSPHONATES - Provided herein are compounds, compositions, and methods of using them to treat infections, neoplastic disease, inflammatory disease, and pain. Such compounds are nucleotides, acyclonucleotides, and ANP phosphonates conjugated with forms and/or moieties of Vitamin B6 for delivery past the cell membrane and into the cell. | 10-23-2014 |
20140329768 | VITAMIN B6 DERIVATIVES OF NUCLEOTIDES, ACYCLONUCLEOTIDES AND ACYCLONUCLEOSIDE PHOSPHONATES - Provided herein are compounds, compositions, and methods of using them to treat infections, neoplastic disease, inflammatory disease, and pain. Such compounds are nucleotides, acyclonucleotides, and ANP phosphonates conjugated with forms and/or moieties of Vitamin B6 for delivery past the cell membrane and into the cell. | 11-06-2014 |